What’s New in Treatment for Castrate-Resistant Prostate Cancer?

    Emma Shtivelman, PhD

    About 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already spread beyond the prostate;… Read more »